Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights, Forecast to 2025

Publisher Name :
Date: 08-May-2019
No. of pages: 119
Inquire Before Buying

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.

PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.

The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at 1205 million US$ in 2018 and will reach 8777.6 million US$ by the end of 2025, growing at a CAGR of 32.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the PARP (Poly ADP-Ribose Polymerase) Inhibitor market based on company, product type, end user and key regions.

This report studies the global market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of PARP (Poly ADP-Ribose Polymerase) Inhibitor in these regions.

This research report categorizes the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market by top players/brands, region, type and end user. This report also studies the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:

- AstraZeneca

- Tesaro

- Merck & Co

- Clovis Oncology

- Pfizer

PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by Type

- Lynparza

- Zejula

- Rubraca

- Talzenna

- Other

PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by Applications

- Ovarian Cancer

- Breast Cancer

- Other

Market size by Region

- North America

- - United States

- - Canada

- - Mexico

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Europe

- - Germany

- - France

- - UK

- - Italy

- - Spain

- - Russia

- Central & South America

- - Brazil

- - Rest of Central & South America

- Middle East & Africa

- - Turkey

- - GCC Countries

- - Egypt

- - South Africa

The study objectives of this report are:

- To study and analyze the global PARP (Poly ADP-Ribose Polymerase) Inhibitor market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.

- To understand the structure of PARP (Poly ADP-Ribose Polymerase) Inhibitor market by identifying its various subsegments.

- To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

- Focuses on the key global PARP (Poly ADP-Ribose Polymerase) Inhibitor companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.

- To project the value and sales volume of PARP (Poly ADP-Ribose Polymerase) Inhibitor submarkets, with respect to key regions.

- To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor are as follows:

- History Year: 2014-2018

- Base Year: 2018

- Estimated Year: 2019

- Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of PARP (Poly ADP-Ribose Polymerase) Inhibitor market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Insights, Forecast to 2025

Table of Contents
1 Study Coverage
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Introduction
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Type
1.4.2 Lynparza
1.4.3 Zejula
1.4.4 Rubraca
1.4.5 Talzenna
1.4.6 Other
1.5 Market by Application
1.5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Application
1.5.2 Ovarian Cancer
1.5.3 Breast Cancer
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size
2.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue 2014-2025
2.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2014-2025
2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Growth Rate by Regions
2.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Regions
2.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
3.1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers
3.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Manufacturers
3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers
3.2.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2014-2019)
3.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2014-2019)
3.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Manufacturers
3.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturing Base Distribution, Product Types
3.4.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
3.4.3 Date of International Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type
4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type
4.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type
5 Breakdown Data by Application
5.1 Overview
5.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Breakdown Data by Application
6 North America
6.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
6.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
6.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
6.3 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
7 Europe
7.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
7.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
7.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
7.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
8 Asia Pacific
8.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
8.1.1 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
8.1.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
8.3 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
9 Central & South America
9.1 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
9.1.1 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
9.1.2 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
9.1.3 Brazil
9.1.4 Argentina
9.2 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
9.3 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
10 Middle East and Africa
10.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
10.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country
10.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Type
10.3 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 Company Business Overview
11.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.1.4 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.1.5 AstraZeneca Recent Development
11.2 Tesaro
11.2.1 Tesaro Company Details
11.2.2 Company Business Overview
11.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.2.5 Tesaro Recent Development
11.3 Merck & Co
11.3.1 Merck & Co Company Details
11.3.2 Company Business Overview
11.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.3.5 Merck & Co Recent Development
11.4 Clovis Oncology
11.4.1 Clovis Oncology Company Details
11.4.2 Company Business Overview
11.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.4.5 Clovis Oncology Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Company Business Overview
11.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Products Offered
11.5.5 Pfizer Recent Development
12 Future Forecast
12.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions
12.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Regions 2019-2025
12.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Regions 2019-2025
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type
12.2.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type 2019-2025
12.2.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Type 2019-2025
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application
12.4 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.5 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.6 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.7 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
12.8 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables and Figures
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Picture
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segments
Table Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Covered
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Type 2019-2025 (K Units) & (Million US$)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2018 & 2025
Figure Lynparza Product Picture
Table Major Manufacturers of Lynparza
Figure Zejula Product Picture
Table Major Manufacturers of Zejula
Figure Rubraca Product Picture
Table Major Manufacturers of Rubraca
Figure Talzenna Product Picture
Table Major Manufacturers of Talzenna
Figure Other Product Picture
Table Major Manufacturers of Other
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size Growth Rate by Application 2019-2025 (K Units)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor 4900 Sales Market Share by Application in 2018
Figure Ovarian Cancer
Figure Breast Cancer
Figure Other
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Report Years Considered
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size 2014-2025 (Million US$)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales 2014-2025 (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Regions 2014-2019 (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions 2014-2019
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions 2014-2019
Figure 2018 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Regions
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Regions 2014-2019 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions 2014-2019
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions 2014-2019
Figure 2018 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Regions
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Manufacturers (2014-2019) (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Manufacturers (2014-2019) (Million USD)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Manufacturers (2014-2019)
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Share by Manufacturers in 2018
Table Key Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Price (2014-2019) (USD/Unit)
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers PARP (Poly ADP-Ribose Polymerase) Inhibitor Product Type
Table Date of International Manufacturers Enter into PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Type (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type in 2018
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Type (2014-2019) (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Share by Type (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type (2014-2019)
Figure Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Type in 2018
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Price by Type 2014-2019 (USD/Unit)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Share by Application (2014-2019)
Figure Global Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application (2014-2019)
Figure Global Sales PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application in 2018
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K Units)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2014-2019) (K Units)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2014-2019) (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (K Units)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
Figure 2018 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K Units)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2014-2019) (K Units)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2014-2019) (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure France PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
Figure 2018 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2014-2019) (K Units)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2014-2019) (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure China PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure India PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Australia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Philippines PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Thailand PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Singapore PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
Figure 2018 Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2014-2019) (K Units)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2014-2019) (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
Figure 2018 Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Country (2014-2019) (K Units)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Country
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue by Country (2014-2019) (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share by Country
Figure GCC Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate (2014-2019) (K Units)
Figure South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Type (2014-2019) (K Units)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Type (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Type
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales by Application (2014-2019) (K Units)
Table Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
Figure 2018 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share by Application
Table AstraZeneca Company Details
Table AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table AstraZeneca Recent Development
Table Tesaro Company Details
Table Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Tesaro Recent Development
Table Merck & Co Company Details
Table Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Merck & Co Recent Development
Table Clovis Oncology Company Details
Table Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Clovis Oncology Recent Development
Table Pfizer Company Details
Table Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pfizer Recent Development
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Regions 2019-2025 (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Regions 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Regions 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type 2019-2025 (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Type 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Forecast by Type 2019-2025 (Million US$)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Market Share Forecast by Type 2019-2025
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application 2019-2025 (K Units)
Table Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share Forecast by Application 2019-2025
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Key Opportunities and Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Table Market Risks
Figure Porter's Five Forces Analysis
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Value Chain
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Customers List
Figure Channels of Distribution
Table PARP (Poly ADP-Ribose Polymerase) Inhibitor Distributors List
Figure Distributors Profiles
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Figure Key Executives Interviewed
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
    Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118
    The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......
  • Global Non-imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90
    The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
  • Global PCR Equipment Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77
    The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......
  • Global Disposable Sterile Syringes and Needles Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109
    The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......
  • Global Orthopaedic Power Tools Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
  • Global Cerebrospinal Fluid Management Devices Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
  • Global CAD & CAM Milling Burs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
  • Global Artificial Teeth Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98
    The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs